These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34391591)

  • 1. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.
    Campochiaro C; Farina N; Tomelleri A; Ferrara R; Lazzari C; De Luca G; Bulotta A; Signorelli D; Palmisano A; Vignale D; Peretto G; Sala S; Esposito A; Garassino M; Gregorc V; Dagna L
    Eur J Intern Med; 2021 Nov; 93():87-94. PubMed ID: 34391591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy.
    Medina P; Jeffers KD; Trinh VA; Harvey RD
    J Pharm Pract; 2020 Jun; 33(3):338-349. PubMed ID: 31694455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
    Fa'ak F; Buni M; Falohun A; Lu H; Song J; Johnson DH; Zobniw CM; Trinh VA; Awiwi MO; Tahon NH; Elsayes KM; Ludford K; Montazari EJ; Chernis J; Dimitrova M; Sandigursky S; Sparks JA; Abu-Shawer O; Rahma O; Thanarajasingam U; Zeman AM; Talukder R; Singh N; Chung SH; Grivas P; Daher M; Abudayyeh A; Osman I; Weber J; Tayar JH; Suarez-Almazor ME; Abdel-Wahab N; Diab A
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37328287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
    Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
    J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
    Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
    Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
    Kim ST; Tayar J; Trinh VA; Suarez-Almazor M; Garcia S; Hwu P; Johnson DH; Uemura M; Diab A
    Ann Rheum Dis; 2017 Dec; 76(12):2061-2064. PubMed ID: 28830882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.
    Kijima T; Fukushima H; Kusuhara S; Tanaka H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Sakai Y; Saito K; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
    Clin Genitourin Cancer; 2021 Jun; 19(3):208-216.e1. PubMed ID: 32800718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
    Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
    Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.